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inhibitor (RG7128) and danoprevir for chronic hepatitis C
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30;376(9751):1467–75. Reprinted from The Lancet, Copyright
(2010), with permission from Elsevier.
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Abstract: Background: Present interferon-based standard of care
treatment for chronic hepatitis C virus (HCV) infection is limited by
both efﬁcacy and tolerability. We assessed the safety, tolerability,
and antiviral activity of an all-oral combination treatment with
two experimental anti-HCV drugs-RG7128, a nucleoside polymerase
inhibitor; and danoprevir, an NS3/4A protease inhibitor-in patients
with chronic HCV infection.
Methods: Patients from six centres in New Zealand and Australia
who were chronically infected with HCV genotype 1 received up to
13 days oral combination treatment with RG7128 (500 or 1000 mg
twice daily) and danoprevir (100 or 200 mg every 8 h or 600 or
900 mg twice daily) or placebo. Eligible patients were sequentially
enrolled into one of seven treatment cohorts and were randomly
assigned by interactive voice or web response system to either active
treatment or placebo. Patients were separately randomly assigned
within each cohort with a block size that reﬂected the number of
patients in the cohort and the ratio of treatment to placebo. The ran-
dom allocation schedule was computer generated. Dose escalation
was started in HCV treatment-naive patients; standard of care treat-
ment-experienced patients, including previous null responders, were
enrolled in higher-dose danoprevir cohorts. Investigators, personnel
at the study centre, and patients were masked to treatment alloca-
tion. However, the pharmacist who prepared the doses, personnel
involved in pharmacokinetic sample analyses, statisticians who pre-
pared data summaries, and the clinical pharmacologists who
reviewed the data before deciding to initiate dosing in the next
cohort were not masked to treatment allocation. The primary out-
come was change in HCV RNA concentration from baseline to day
14 in patients who received 13 days of combination treatment. AllJournal of Hepatology 20
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Findings: Eighty-eight patients were randomly assigned to a study
drug treatment regimen (n = 74 over seven treatment groups; 73
received at least one dose of study drug) or to placebo (n = 14, all
of whom received at least one dose). The median change in HCV
RNA concentration from baseline to day 14 ranged from 3.7 to
5.2 log(10) IU/ml in the cohorts that received 13 days of combina-
tion treatment. At the highest combination doses tested (1000 mg
RG7128 and 900 mg danoprevir twice daily), the median change in
HCV RNA concentration from baseline to day 14 was 5.1
log(10) IU/ml (IQR-5.6 to 4.7) in treatment-naive patients and
4.9 log(10) IU/ml in previous standard of care null responders
(5.2 to 4.5) compared with an increase of 0.1 log(10) IU/ml in
the placebo group. The combination of RG7128 and danoprevir
was well tolerated with no treatment-related serious or severe
adverse events, no grade 3 or 4 changes in laboratory parameters,
and no safety-related treatment discontinuations.
Interpretation: This oral combination of a nucleoside analogue
polymerase inhibitor and protease inhibitor holds promise as an
interferon-free treatment for chronic HCV. 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
In the last decade, insights into the virology of HCV have unrav-
elled several targets for potential novel therapeutics that, unlike
interferon (IFN)-a and ribavirin, are speciﬁcally targeted to HCV.
Several new drug therapies, such as protease and polymerase
inhibitors, designated as direct-acting antivirals (DAAs), have
reached clinical development [1,2]. Gane and colleagues have
recently published in the Lancet the results of the ﬁrst study with
a combination of two (DAAs) without interferon (IFN) or ribavirin
in patients with chronic hepatitis C. The aim of the proof-of-con-
cept INFORM-1 trial was to assess the efﬁcacy and safety of the
combination of two drugs in development, danoprevir, an NS3/
4A protease inhibitor, and RG7128, a nucleoside analogue inhib-
itor of HCV RNA-dependent RNA polymerase, over 2 weeks of
administration. In this randomised, double-blind, placebo-con-
trolled trial, 88 patients infected with HCV genotype 1 were
enrolled into one of seven treatment arms, randomised to differ-
ent doses and schedules of study drugs or placebo for up to
13 days. Then, patients were rolled over into the current standard
of care (SOC), i.e. pegylated interferon (PEG-IFN) and ribavirin11 vol. 55 j 933–935
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Fig. 1. Early viral kinetic proﬁle of danoprevir and RG7128 combination.
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(RBV). The vast majority of patients had never been treated
before, whereas 16 of them had failed to eradicate HCV with
SOC. The main ﬁnding of the study was the demonstration of a
substantial, sustained, dose-dependent HCV RNA level reduction,
whatever the treatment group. The viral level reduction reached
5 log on average after 14 days of combination with the highest
drug doses i.e. 1000 mg b.i.d of RG7128 and 900 mg b.i.d. of dano-
previr. Undetectable HCV-RNA (<15 IU/ml) was achieved in 44%
of patients overall. The antiviral efﬁcacy was similar in treat-
ment-naïve patients and in patients who failed to eradicate
HCV after a ﬁrst course with PEG-IFN and RBV, including null-
responders included in the highest dose group. No evidence of
emergence of HCV variants resistant to either compound was
reported during the short-term administration of the drugs.
Treatment was well tolerated and no serious adverse event, dose
modiﬁcation, or premature discontinuation were reported over
the 2 weeks of administration.
Virtually any step of the HCV lifecycle can be a target for HCV
inhibitors. The most successful approach so far has been targeting
the HCV protease. The triple combination of PEG-IFN, RBV, and a
ﬁrst-generation protease inhibitor (telaprevir or boceprevir) will
increase the sustained virologic response (SVR) rates from 40–
44% to 68–75% in treatment-naïve patients infected with HCV
genotype 1 [3,4]. This treatment is expected to become the new
SOC at the end of 2011-beginning of 2012 in treatment-naïve
and treatment-experienced patients infected with genotype 1.
However, this therapy will not be optimal for patients who are
intolerant or have contra-indications to PEG-IFN or RBV, includ-
ing for instance patients with decompensated cirrhosis or hemo-
globinopathies. In the phase 3 registration trials, more than 10%
of the carefully selected patients discontinued triple combination
therapy prematurely due to adverse events. Moreover, the efﬁ-
cacy of the triple combination will be limited in treatment-expe-
rienced patients who did not respond to PEG-IFN and ribavirin by
more than 1 log drop in HCV RNA levels at week 4, with a high
risk of treatment failure and the selection of HCV variants resis-
tant to protease inhibitors [5,6]. Finally, triple therapy will most
likely not be able to eradicate HCV in a number of so-called ‘‘dif-
ﬁcult-to-treat’’ patients. Thus, PEG-IFN and/or RBV intolerant or
poorly responsive patients could be the main beneﬁciaries of
interferon-sparing HCV treatment regimens, and one cannot
exclude that IFN-free regimens will become SOC ﬁrst-line treat-
ment for all patients with chronic HCV infection.
The main objectives of a regimen combining DAAs without
IFN or ribavirin should be: (a) to improve antiviral efﬁcacy with-
out increasing toxicity; (b) to prevent the development of resis-
tance by combining DAAs targeting different elements of the
HCV life cycle and without cross-resistance; and (c) to avoid
drug–drug interactions without impairing safety. Although the
present study met the short-term safety objective and direct
interactions between the two drugs could be considered unlikely,
it presents some limitations. Due to the short duration of admin-
istration of the study drugs, the long-term safety proﬁle, and the
risk of late rebound due to viral resistance to the combination
remain unknown. The goal of antiviral treatment is to cure HCV
infection, as witnessed by the sustained virological response,
characterized by an undetectable HCV RNA 6 months after the
end of therapy. Because the patients were all treated with the
combination of PEG-IFN and ribavirin after the 2-week IFN-free
regimen, the fact that the observed early pronounced antiviral
activity of the combination of two DAAs could lead to HCV erad-934 Journal of Hepatology 201ication has not been proven. However, interestingly, the early
kinetics of HCV RNA levels with the DAA combination appeared
to be similar to those reported in a previous study with a similar
population receiving danoprevir in combination with PEG-IFN
and ribavirin. The initial HCV RNA decline was rapid, especially
during the ﬁrst two days (ﬁrst phase decline: 3.5 log on average
with the highest drug doses in treatment-naïve patients), corre-
sponding to the clearance of free HCV virions. The second slope
was slower (HCV-RNA decline: 1.0 log per week on average),
related to the loss of infected hepatocytes (Fig. 1). Based on an
estimated total body viral burden of 1011 virions, 8–12 weeks
of DAA treatment could be sufﬁcient to eradicate HCV infection
in most patients, provided that no relapse occurs as a result of
resistant variant selection. The possibility to cure HCV infection
with DAA combinations without IFN (with or without ribavirin)
should be assessed in future studies with longer treatment dura-
tions in both treatment-naïve and – experienced patients, as all-
oral, IFN-free regimens should be effective in both patient
populations.
Current and future trials will likely determine whether the
IL28B genotype and IP-10 levels inﬂuence SVR when patients
are treated with DAA combinations without IFN. The impact of
RBV on the efﬁcacy and safety of DAA combinations has to be
established. Based on the observation of higher relapse and viral
breakthrough rates in the RBV-sparing treatment arms in the
telaprevir plus SOC studies [5,7] and on the fact that RBV could
accelerate the second slope of viral decline and prevent break-
through due to resistance when administered in combination
with two DAAs with a low genetic barrier to resistance [8], the
impact of RBV on efﬁcacy and safety of combination DAA therapy
has to be established. Although telaprevir has shown potent anti-
viral activity against HCV genotype 2, it has no effect on HCV
genotype 3, suggesting that PEG-IFN and RBV will remain the
SOC for non HCV genotype 1 patients [9]. However, other prote-
ase inhibitors, as well as nucleoside/nucleotide analogues and
cyclophillin inhibitors, have shown antiviral potency against
genotypes other than 1. Thus, IFN-sparing combination regimens
could be studied in other patient populations than those included
in INFORM-1.1 vol. 55 j 933–935
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Several trials of combination DAAs are ongoing in treatment-
naïve or experienced patients. All studies include protease
inhibitor, combined with either a NS5A, non-nucleoside NS5B,
nucleoside NS5B inhibitor. The second DAA must be chosen
carefully, as recent data suggest that the genetic barrier of com-
bination therapy with a ﬁrst-generation protease inhibitor and a
non-nucleoside NS5B or an NS5A inhibitor is not higher than that
of protease inhibitor monotherapy [8,10]. In contrast, the absence
of occurrence of breakthroughs during this trial is probably
related to the high barrier resistance of the danoprevir and
RG7128 combination.
In conclusion, this proof-of-concept INFORM-1 trial has
shown that the combination of danoprevir and RG7128 for up
to 13 days results in a substantial biphasic HCV-RNA decline,
without selecting HCV variants and with a satisfactory safety pro-
ﬁle in both treatment-naïve and treatment-experienced patients
infected with HCV genotype 1. Further trials with these drugs or
other DAAs, with or without ribavirin are now needed to assess
whether IFN-free regimens may provide high cure rates in the
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